✦ LIBER ✦

Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial

✍ Scribed by Per Soelberg Sorensen; Jan Lycke; Juha-Pekka Erälinna; Astrid Edland; Xingchen Wu; Jette Lautrup Frederiksen; Annette Oturai; Clas Malmeström; Egon Stenager; Finn Sellebjerg; Helle Bach Sondergaard

Book ID: 114409843
Publisher: The Lancet
Year: 2011
Tongue: English
Weight: 349 KB
Volume: 10
Category: Article
ISSN: 1474-4465
DOI: 10.1016/s1474-4422(11)70144-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

NORdic trial of oral Methylprednisolone

NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial

✍ Per Soelberg Sorensen; Svein Ivar Mellgren; Anders Svenningsson; Irina Elovaara; 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 175 KB

Daclizumab in active relapsing multiple

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

✍ Daniel Wynn; Michael Kaufman; Xavier Montalban; Timothy Vollmer; Jack Simon; Jac 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 456 KB

Alemtuzumab versus interferon beta 1a as

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

✍ Jeffrey A Cohen; Alasdair J Coles; Douglas L Arnold; Christian Confavreux; Edwar 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 334 KB

Methylprednisolone in combination with i

Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial

✍ Mads Ravnborg; Per Soelberg Sørensen; Magnus Andersson; Elisabeth G Celius; Pete 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 374 KB

Efficacy of vitamin D3 as add-on therapy

Efficacy of vitamin D3 as add-on therapy in patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon beta-1a: A Phase II, multicenter, double-blind, randomized, placebo-controlled trial

✍ Joost Smolders; Raymond Hupperts; Frederik Barkhof; Luigi M.E. Grimaldi; Trygve 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 355 KB

A double blind, placebo-controlled, phas

A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN

✍ F Patti; M.P Amato; M Filippi; P Gallo; M Trojano; G.C Comi 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 72 KB